Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 14NIH 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Neutropenia 11Leukemia, Myeloid, Acute 9Breast Neoplasms 7Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Plasmacytoma 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Plasma Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Febrile Neutropenia 2Anemia, Refractory, with Excess of Blasts 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neutropenia in Breast Cancer 1Myelodysplastic Syndromes 1Medulloblastoma 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 65Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 30Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Rituximab 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Filgrastim × Clear all
NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT00066092 2008-02-28

Pegfilgrastim PBPC Mobilization Study

Amgen

Phase 2 Completed
41 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡